RENB-DC-12-XX

N/A

Report date: 2023/10/26 17:28:32

Base Information

Drug NameRENB-DC-12-XX

Drug Alias NameENOB-DC-12-XXRENB-DC-12-XX

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccineCell and gene therapy > Gene therapy

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRenovaro Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesRenovaro Biosciences Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A